--- title: "Weekly Recap | Sellas Life Sciences -14.55%, consensus target more than double spot" type: "News" locale: "en" url: "https://longbridge.com/en/news/297390527.md" description: "Sellas Life Sciences (SLS) fell 14.55% this week to close at $13.21. The S&P 500 rose 0.49% over the same period, leaving the stock about 15.04 percentage points behind the benchmark. The daily path was uneven. Monday opened at $15.475 and slid to $14.325 by the close. Tuesday and Wednesday pushed lower, with Wednesday touching $13.410 intraday. Thursday bounced to $15.210, posting the week’s highest daily volume at 12.1m shares. Friday reversed again, dropping to a low of $13." datetime: "2026-08-29T06:25:10.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/297390527.md) - [en](https://longbridge.com/en/news/297390527.md) - [zh-HK](https://longbridge.com/zh-HK/news/297390527.md) generator: "portal-rs" --- # Weekly Recap | Sellas Life Sciences -14.55%, consensus target more than double spot ## The Week Sellas Life Sciences (SLS) fell 14.55% this week to close at $13.21. The S&P 500 rose 0.49% over the same period, leaving the stock about 15.04 percentage points behind the benchmark. The daily path was uneven. Monday opened at $15.475 and slid to $14.325 by the close. Tuesday and Wednesday pushed lower, with Wednesday touching $13.410 intraday. Thursday bounced to $15.210, posting the week’s highest daily volume at 12.1m shares. Friday reversed again, dropping to a low of $13.150 before settling at $13.210. Weekly amplitude came to 15.57%, and average daily volume of 8.7m shares ran about 28% above the 60-day median. ## Key Events The week’s news followed two threads. On Monday, options data showed some call options had surged 228% after the stock gained 15% the previous Friday, pointing to elevated short-term volatility pricing in derivatives. The same day, Quantinno Capital Management LP disclosed a new position worth roughly $315,000 in SELLAS Life Sciences. On Friday, a report on Revolution Medicines’ FDA approval lifted sentiment across the sector, and SELLAS shares moved in sympathy. The three items lined up with early-week options activity, a mid-week institutional disclosure, and sector-driven movement near the weekend. ## Analyst Ratings Two firms cover the stock: one rates it buy and one rates it overweight, with no hold, underweight, or sell ratings. The consensus rating is buy, and the consensus target price is $32.50, implying roughly 146% upside from the latest price of $13.21. Targets range narrowly from $30 to $35. Within the biotechnology industry group of 505 companies, the stock ranks 410th in analyst ratings, placing it in the lower portion of the peer set. ## The Week Ahead Next week brings a dense run of US macro data. Monday features the Dallas Fed manufacturing business activity index. Tuesday includes the S&P Global manufacturing PMI final, the ISM manufacturing PMI, and JOLTS job openings. Wednesday adds ADP private payrolls, factory orders, and EIA crude inventories. No company-specific earnings or major events are currently scheduled for next week. After Friday’s sharp late-week pullback, whether the stock can hold the area near $13 will be a key technical focus in early trading. ## In Short Sellas dropped more than 14% this week, yet the consensus target price still sits more than double the spot price, leaving the ratings picture tilted positive. At the same time, earnings are negative, the price-to-book ratio is around 19x, and the latest session’s flows show large-lot money as a net seller. The tension sits between a constructive analyst view and a weaker near-term tape. The next question is whether the stock can stabilise near $13 and whether the sector’s sentiment holds. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [SLS.US](https://longbridge.com/en/quote/SLS.US.md) ## Related News & Research - [SELLAS Stock Draws Fresh Attention As Cancer Vaccine Trials Gain Ground](https://longbridge.com/en/news/299907577.md) - [Frank Gerola's BMF Targets SELLAS Life Sciences $3 Billion Valuation: Biotech's 'Most Expensive Coin Flip'](https://longbridge.com/en/news/297477201.md) - [Missed IMAX’s 56% Run? What The Market Kept Getting Wrong](https://longbridge.com/en/news/300866816.md) - [Average analyst price target for Accsys Technologies increased by 11.37% to €0.01](https://longbridge.com/en/news/300865749.md) - [Gartner (IT) Could Be 37% Below Fair Value Following Mixed Momentum](https://longbridge.com/en/news/300865157.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**